A5017579565- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- SARS-CoV-2 detection and testing
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- Viral gastroenteritis research and epidemiology
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Long-Term Effects of COVID-19
- Animal Virus Infections Studies
- Viral Infections and Immunology Research
- Hepatitis C virus research
- Viral Infections and Outbreaks Research
- Infectious Diseases and Tuberculosis
- Liver Disease Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- interferon and immune responses
University Hospital Cologne
2016-2025
University of Cologne
2013-2025
German Center for Infection Research
2016-2025
Institute of Virology of the Slovak Academy of Sciences
2021-2023
Universität Hamburg
2015-2022
University Medical Center Hamburg-Eppendorf
2015-2022
Charité - Universitätsmedizin Berlin
2022
L'Hôpital Nord Franche-Comté
2022
Bernhard Nocht Institute for Tropical Medicine
2022
Eppendorf (Belgium)
2022
Fast and reliable detection of patients with severe heterogeneous illnesses is a major goal precision medicine1,2. Patients leukaemia can be identified using machine learning on the basis their blood transcriptomes3. However, there an increasing divide between what technically possible allowed, because privacy legislation4,5. Here, to facilitate integration any medical data from owner worldwide without violating laws, we introduce Swarm Learning-a decentralized machine-learning approach that...
The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the globe. This new concern carries an unusually high number mutations key epitopes neutralizing antibodies on viral spike glycoprotein, suggesting potential immune evasion. Here we assessed serum capacity longitudinal cohorts vaccinated and convalescent individuals, as well monoclonal antibody activity against using pseudovirus neutralization assays. We report near-complete lack polyclonal sera from...
The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs vaccines are limited or not available, new options COVID-19 treatment prevention in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed antibody response of 12 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, isolated 255 antibodies different time points as early Of these, 27 potently neutralized...
Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 infection. However, viral escape through mutation of the envelope glycoprotein (Env) limits clinical applications. Here we describe 1-18, new VH1-46-encoded CD4 binding site (CD4bs) bNAb with outstanding breadth (97%) potency (GeoMean IC50 = 0.048 μg/mL). Notably, 1-18 is not susceptible typical CD4bs mutations effectively overcomes resistance other bNAbs. Moreover, mutational antigenic...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are potential therapeutic agents. We identified SF12 related bNAbs with up to 62% neutralization breadth from an HIV-infected donor. recognized a glycan-dominated epitope on Env's silent face was potent clade AE viruses, which poorly covered by V3-glycan bNAbs. A 3.3Å cryo-EM structure of SF12-Env trimer complex showed additional contacts Env protein residues compared VRC-PG05, the only other known...
We investigated whether CD4:CD8 ratio and CD8 count were prognostic for all-cause, AIDS, non-AIDS mortality in virologically suppressed patients with high CD4 count.We used data from 13 European North American cohorts of human immunodeficiency virus-infected, antiretroviral therapy (ART)-naive adults who started ART during 1996-2010, followed the date they had ≥350 cells/μL (baseline). stratified Cox models to estimate unadjusted adjusted (for sex, people inject drugs, initiation year,...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a global health emergency. To improve the understanding of systemic component SARS-CoV-2, we investigated if viral load dynamics in plasma and samples are associated with antibody response severity disease 2019 (COVID-19). SARS-CoV-2 RNA was found from 14 (44%) out 32 patients. RNAemia detected 5 6 fatal cases. Peak IgG values were significantly lower mild/moderate than severe (0.6 (interquartile range, IQR, 0.4–3.2) vs....
<title>Abstract</title> The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the globe. This new concern carries an unusually high number mutations key epitopes neutralizing antibodies on viral spike glycoprotein, suggesting potential immune evasion. Here we assessed serum capacity longitudinal cohorts vaccinated and convalescent individuals, as well monoclonal antibody activity against using pseudovirus neutralization assays. We report near-complete lack...
Background COVID-19 has so far affected more than 250 million individuals worldwide, causing 5 deaths. Several risk factors for severe disease have been identified, most of which coincide with advanced age. In younger individuals, often occurs in the absence obvious comorbidities. Guided by finding cytomegalovirus (CMV)-specific T cells some cross-reactivity to SARS-CoV-2 a intensive care unit (ICU) patient, we decided investigate whether CMV seropositivity is associated or critical...
Understanding the specificities of human serum antibodies that broadly neutralize HIV can inform prevention and treatment strategies. Here, we describe a deep mutational scanning system measure effects combinations mutations to envelope (Env) on neutralization by polyclonal serum. We first show this accurately map how all functionally tolerated Env affect monoclonal antibodies. then comprehensively set sera diverse strains target site engaging host receptor CD4. The neutralizing activities...
Out of 302 AIDS-related lymphoma (ARL) patients enrolled in the German ARL cohort study, 18 had plasmablastic (PBL). Twelve out (67%) have died with a median survival 4 months (range 0-11 months). In univariate analysis, an intermediate or high international prognostic index score was associated significantly lower overall and progression-free survival. The predominant cause death progressive (67%). Our data indicate that outcome PBL is still very poor.
Summary Overall survival ( OS ) of patients with acquired immunodeficiency syndrome AIDS )‐related Burkitt lymphoma BL ), diffuse large B‐cell DLBCL and plasmablastic PBL was analysed in the German ‐related‐Lymphoma‐Cohort‐Study. Of 291 prospectively included between January 2005 December 2012, 154 had , 103 34 . Two‐year rates were similar (69%) (63%) but lower for (43%). Intermediate (Hazard ratio [ HR ] 4·1 95% confidence interval CI 1·98–8·49) or high 4·92 2·1–11·61) International...
To study the diversity of immune receptors and pathogens, multiplex PCR has become a central approach in research diagnostics. However, insufficient primer design against highly diverse templates often prevents amplification therefore limits correct understanding biological processes. Here, we present openPrimeR, an R-based tool for evaluating designing primers. openPrimeR provides functional intuitive interface uses either greedy algorithm or integer linear program to compute minimal set...
Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and C (HCV) infection promote NHL HIV-infected patients unclear. Objective: To investigate whether HBV HCV are associated with increased incidence patients. Design: Cohort study. Setting: 18 33 cohorts from Collaboration Observational HIV Epidemiological Research Europe (COHERE). Patients: information on surface antigen measurements...
Bezafibrate (BEZ), a pan activator of peroxisome proliferator–activated receptors (PPARs), has been generally used to treat hyperlipidemia for decades. Clinical trials with type 2 diabetes patients indicated that BEZ also beneficial effects on glucose metabolism, although the underlying mechanisms these remain elusive. Even less is known about potential role in treating 1 diabetes. Here we show markedly improves hyperglycemia and insulin tolerance mice streptozotocin (STZ)-induced diabetes,...
The results of intensive immunochemotherapy were analyzed in human immunodeficiency virus (HIV)-related Burkitt lymphoma/leukemia (BLL) two cohorts (Spain and Germany). Alternating cycles chemotherapy administered, with dose reductions for patients over 55 years. Eighty percent achieved remission, 11% died during induction, 9% failed 7% remission. Four-year overall survival (OS) progression-free (PFS) probabilities 72% (95% confidence interval [CI]: 62-82%) 71% CI: 61-81%). CD4 T-cell count...